Azura Ophthalmics Limited

Will you be at #TFOS2024? Join our Chief Medical Officer, Charles Bosworth, Ph.D. in Venice!   We're excited to attend this year’s meeting and look forward to exchanging valuable information on diagnosing and treating ocular surface disorders.   #Optometry #Ophthalmology )#TFOS2024, #MGD #innovation, #startups, #dryeye, #biotech, #lifesciences, #ophthalmology 

👀 Check out this Eyes On Eyecare piece by Alex Delaney-Gesing to learn more about the significance of the first patient enrolled in ASTRO, a Phase 3 clinical trial evaluating the safety and efficacy of our investigational candidate for the treatment of #MeibomianGlandDysfunction (MGD)   https://lnkd.in/e89kuS97    #Optometry #Ophthalmology #MeibomianGlandDysfunction #Keratolytics

The first patient has enrolled in our U.S.-based Phase 3 clinical trial evaluating the safety and efficacy of our investigational drug candidate for Meibomian Gland Dysfunction (MGD). Learn more in the press release below and stay tuned for updates as we move one step closer to bringing symptom relief to people burdened by MGD and associated ocular surface conditions. #Ophthalmology #Optometry #MeibomianGlandDysfunction #Keratolytics

Today, we announced the first patient has been enrolled in the ASTRO study, a pivotal Phase 3 clinical trial evaluating the efficacy and safety of our investigational drug candidate for Meibomian Gland Dysfunction (MGD). Learn more: https://lnkd.in/geyZm7tZ #Ophthalmology #Optometry #Keratolytics

✈️ Seattle-bound for #ARVO2024?   Learn about the efficacy and safety data from the Phase 2 studies of our lead drug candidate for Meibomian Gland Dysfunction during our 8 poster presentations featuring expert physicians and investigators: https://lnkd.in/g8U_innn   #Ophthalmology

👀 Don’t miss our CEO, Marc Gleeson on Eyewire+ as he reviews the long-term data from our investigational medicine for Meibomian Gland Dysfunction (MGD) at #ASCRS. Watch here: https://lnkd.in/gGx-MJ_y   #Ophthalmology #Optometry 

Join us this morning at Preeya Gupta’s #ASCRS session as she reviews new, long-term data showing durable improvement in signs and symptoms of Meibomian Gland Dysfunction (MGD) after 6 months of treatment with our investigational medicine. #ASCRS2024 #Ophthalmology

Attending #ASCRS2024? Don’t miss Charles Bosworth’s session today at 1:30 pm ET discussing the correlation of patient outcomes with indicators of Meibomian Gland Dysfunction (MGD) after treatment with our investigational medicine. #Ophthalmology #ASCRS

#DYK We will be presenting new and updated data supporting the potential of AZR-MD-001 to be the first Ophthalmic Keratolytic for Ocular Surface Diseases like Meibomian Gland Dysfunction (MGD) at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Conference in Boston. Learn more: bit.ly/49nJC3e #ASCRS #ARVO #Ophthalmology #Optometry #ContactLenseDiscomfort #MeibomianGlandDysfunction #MGD

Want to learn about our investigational drug candidate AZR MD-001 and the recent Ph. 2 study results that show it may be able to extend #ContactLens wear by 3 hours? Read more in the PharmaLeaders.com interview with our CEO, Marc Gleeson: https://bit.ly/48MeZnW   #Ophthalmology #Optometry #ContactLenseDiscomfort #MeibomianGlandDysfunction #MGD #BioPharma